ISHARES TR - U.S. PHARMA ETF (IHE)

Historical Holders from Q1 2014 to Q3 2025

Symbol
IHE
Type / Class
Equity / U.S. PHARMA ETF
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
4,719,905
Holdings value
$342,444,031
% of all portfolios
0%
Number of holders
150
Number of buys
50
Number of sells
-50
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of ISHARES TR - U.S. PHARMA ETF (IHE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 4,719,905 $342,444,031 -$13,869,443 $72.56 150
2025 Q2 4,968,369 $325,628,195 -$8,276,835 $65.54 140
2025 Q1 4,897,901 $345,371,935 -$39,000,021 $70.56 151
2024 Q4 5,467,783 $359,359,917 +$8,463,665 $65.72 156
2024 Q3 5,298,041 $374,021,462 -$36,539,203 $70.61 144
2024 Q2 5,831,524 $386,871,861 +$20,429,427 $66.32 143
2024 Q1 5,585,305 $378,308,781 +$224,982,917 $67.9 140
2023 Q4 2,092,523 $386,524,330 +$264,647,538 $185.4 137
2023 Q3 618,504 $109,495,602 -$4,592,717 $176.98 126
2023 Q2 645,577 $115,762,827 -$10,083,284 $179.11 118
2023 Q1 734,313 $129,088,785 -$4,630,135 $175.28 127
2022 Q4 747,188 $138,995,470 +$9,168,861 $186.13 127
2022 Q3 692,535 $117,426,900 -$7,415,939 $169.54 109
2022 Q2 747,328 $143,356,273 +$33,526,994 $191.65 120
2022 Q1 572,187 $111,243,777 +$8,958,655 $194.25 118
2021 Q4 521,386 $104,202,203 -$3,381,738 $199.66 107
2021 Q3 536,082 $98,232,493 +$981,063 $183.14 107
2021 Q2 529,598 $98,372,552 +$6,457,088 $185.74 99
2021 Q1 494,862 $87,906,779 -$2,280,688 $177.66 99
2020 Q4 506,968 $90,990,918 +$3,797,914 $179.44 98
2020 Q3 486,383 $79,572,611 -$9,004,469 $163.53 92
2020 Q2 544,377 $83,775,755 +$14,643,808 $153.87 89
2020 Q1 452,102 $60,854,809 -$20,553,537 $134.58 92
2019 Q4 599,609 $96,007,160 -$71,298,776 $160.11 91
2019 Q3 1,050,914 $147,043,719 +$43,798,392 $139.85 82
2019 Q2 733,992 $110,709,985 +$8,525,948 $150.79 84
2019 Q1 676,767 $104,199,730 -$235,018 $153.97 90
2018 Q4 686,070 $96,581,468 -$28,851,227 $140.76 94
2018 Q3 879,156 $147,563,653 -$38,842 $167.84 96
2018 Q2 877,348 $132,807,979 -$9,909,076 $151.35 91
2018 Q1 945,004 $139,386,111 -$139,511,090 $147.54 101
2017 Q4 1,851,023 $285,754,473 -$31,401,818 $154.38 107
2017 Q3 2,029,359 $317,355,482 -$32,578,466 $156.36 100
2017 Q2 2,243,445 $348,068,556 -$8,951,364 $155.13 93
2017 Q1 2,302,977 $347,593,226 +$60,440,664 $150.94 95
2016 Q4 1,953,627 $276,365,000 +$114,945,783 $141.42 92
2016 Q3 1,120,283 $166,549,000 -$45,855,195 $149.44 85
2016 Q2 1,360,676 $196,592,354 -$20,154,851 $144.4 87
2016 Q1 1,493,203 $204,733,027 -$99,284,833 $136.98 89
2015 Q4 2,215,257 $357,839,814 +$3,571,560 $161.69 103
2015 Q3 2,164,584 $321,148,738 -$24,327,846 $148.02 102
2015 Q2 2,310,854 $404,115,318 -$39,781,267 $174.82 119
2015 Q1 2,536,179 $437,086,452 +$86,720,586 $172.42 107
2014 Q4 2,053,922 $310,975,960 +$27,141,841 $151.4 101
2014 Q3 1,843,426 $258,684,490 -$10,400,827 $140.35 85
2014 Q2 1,917,704 $259,124,112 -$2,844,652 $135.11 87
2014 Q1 1,947,976 $246,645,151 +$26,478,475 $126.69 86